eflornithine has been researched along with Neglected Diseases in 6 studies
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.
eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.
Neglected Diseases: Diseases that are underfunded and have low name recognition but are major burdens in less developed countries. The World Health Organization has designated six tropical infectious diseases as being neglected in industrialized countries that are endemic in many developing countries (HELMINTHIASIS; LEPROSY; LYMPHATIC FILARIASIS; ONCHOCERCIASIS; SCHISTOSOMIASIS; and TRACHOMA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Human African trypanosomiasis (HAT) is a disease caused by infection with the parasite Trypanosoma brucei gambiense or T." | 2.52 | A literature review of economic evaluations for a neglected tropical disease: human African trypanosomiasis ("sleeping sickness"). ( Goeree, R; Sutherland, CS; Tediosi, F; Yukich, J, 2015) |
| "Human African trypanosomiasis (HAT) has been neglected for a long time." | 2.49 | Drug discovery and human African trypanosomiasis: a disease less neglected? ( Baell, JB; Ferrins, L; Rahmani, R, 2013) |
| " Our compound optimization that has led to synthesis of several potent 4-anilinoquinazolines, including NEU617, 23a, a highly potent, orally bioavailable inhibitor of trypanosome replication." | 1.39 | Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis. ( Behera, R; Edwards, P; Guyett, PJ; Karver, CE; Mensa-Wilmot, K; Patel, G; Pollastri, MP; Roncal, NE; Sullenberger, C, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Patel, G | 1 |
| Karver, CE | 1 |
| Behera, R | 1 |
| Guyett, PJ | 1 |
| Sullenberger, C | 1 |
| Edwards, P | 1 |
| Roncal, NE | 1 |
| Mensa-Wilmot, K | 1 |
| Pollastri, MP | 2 |
| Stich, A | 1 |
| Ponte-Sucre, A | 1 |
| Holzgrabe, U | 1 |
| Ferrins, L | 1 |
| Rahmani, R | 1 |
| Baell, JB | 1 |
| Sutherland, CS | 1 |
| Yukich, J | 1 |
| Goeree, R | 1 |
| Tediosi, F | 1 |
| Fonseca, MS | 1 |
| Comini, MA | 1 |
| Resende, BV | 1 |
| Santi, AM | 1 |
| Zoboli, AP | 1 |
| Moreira, DS | 1 |
| Murta, SM | 1 |
| Campbell, RK | 1 |
2 reviews available for eflornithine and Neglected Diseases
| Article | Year |
|---|---|
Drug discovery and human African trypanosomiasis: a disease less neglected?
Topics: Clinical Trials as Topic; Drug Evaluation, Preclinical; Eflornithine; Humans; Neglected Diseases; Sm | 2013 |
A literature review of economic evaluations for a neglected tropical disease: human African trypanosomiasis ("sleeping sickness").
Topics: Africa; Animals; Cost-Benefit Analysis; Eflornithine; Humans; Insect Vectors; Models, Theoretical; N | 2015 |
4 other studies available for eflornithine and Neglected Diseases
| Article | Year |
|---|---|
Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Cell Survival; Coloring Agents; Drug Design; Drug Discovery; | 2013 |
Do we need new drugs against human African trypanosomiasis?
Topics: Animals; Clinical Trials as Topic; Disease Outbreaks; Drug Evaluation, Preclinical; Eflornithine; Hu | 2013 |
Ornithine decarboxylase or gamma-glutamylcysteine synthetase overexpression protects Leishmania (Vianna) guyanensis against antimony.
Topics: Animals; Antimony; Blotting, Western; Buthionine Sulfoximine; Eflornithine; Enzyme Inhibitors; Gene | 2017 |
Target repurposing for neglected diseases.
Topics: Acyltransferases; Drug Discovery; Eflornithine; Enzyme Inhibitors; HIV; HIV Protease; HIV Protease I | 2011 |